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Abstract
Background: Graft local infusion and splenectomy in ABO-incompatible (ABO-I) living donor liver
transplantation (LDLT) are associated with high rates of operative complications.
Methods: Consecutive ABO-I LDLT patients treated at the National Cancer Centre between January
2012 and February 2013 were identified. The protocol for ABO-I LDLT at the study centre included the
administration of rituximab (300 mg/m2) at 2 weeks preoperatively, followed by plasma exchanges (target
isoagglutinin titre: ≤1 : 8), basiliximab (20 mg on the day of surgery and on postoperative day 4), and i.v.
immunoglobulin (0.8 g/kg on postoperative days 1 and 4) without graft local infusion or splenectomy.
Results: Fifteen patients (11 men and four women) who underwent transplantation for liver cirrhosis
(n = 3) or hepatocellular carcinoma (n = 12) were identified. These included 13 patients with hepatitis B
virus infection, one with hepatitis C virus infection and one with alcoholic cirrhosis. The mean age, mean
Model for End-stage Liver Disease (MELD) score and mean graft-to-recipient weight ratio (GRWR) of
these patients was 51.8 years, 11.5 and 0.84, respectively. The median isoagglutinin titre before plasma
exchange was 1 : 32 (range: 1 : 4 to 1 : 256). There were no hyperacute or antibody-mediated rejections.
No bacterial or fungal infections were observed. Complications included herpes zoster viral infection in
one patient, postoperative bleeding in one patient and extrahepatic biliary stricture in three patients.
Conclusions: This simplified ABO-I LDLT protocol showed good graft outcomes without immunologic
failure or serious infections.
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Introduction
In living donor liver transplantation (LDLT), ABO incompatibil-
ity (ABO-I) is regarded as a relative contraindication, except in
urgent cases, because of the likelihood of severe rejection, hepatic
arterial thrombosis and biliary complications.1–3 As understand-
ing of humoral rejection has improved, various strategies to over-
come ABO-I in liver transplantation have been introduced. These
include the use of plasma exchange, graft local infusion, splenec-
tomy, aggressive immunosuppressive agents, and a monoclonal
antibody such as rituximab.4–6
In particular, local graft infusion therapy, which involves the
administration of protease inhibitors, prostaglandin and steroids
through the hepatic artery or portal vein, has dramatically
increased survival in ABO-I LDLT patients.6–8 This therapy has
been considered as an inevitable step towards overcoming ABO
blood type barriers. However, catheter-related complications
associated with local infusion therapy have been reported to
include vascular thrombosis, vascular injury, bleeding and infec-
tions.6 Splenectomy has been performed routinely in ABO-I LDLT
in many centres.9–11 The spleen is the body’s major antibody-
producing organ, and contains large amounts of B cells and
plasma cells. It also fulfils particular functions in blood filtration,
phagocytosis, erythrocyte destruction, antigen uptake and poten-
tial haemopoiesis. However, splenectomy in ABO-I LDLT carries
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risks for severe post-transplant infection and portal vein throm-
bosis.12,13 Splenectomy in cases of advanced liver cirrhosis is dan-
gerous and is associated with intra- or postoperative bleeding as a
result of splenomegaly. In the post-rituximab era, the clinical sig-
nificance of splenectomy in ABO-I LDLT remains controversial.14
In the present study, 15 ABO-I LDLT patients were treated
using a simplified protocol involving rituximab, plasmapheresis,
basiliximab and i.v. immunoglobulin (IG) without any additional
surgical procedures, such as local graft infusion or splenectomy.
The results indicate the potential value of an approach based on
routine surgical procedures in LDLT and excluding splenectomy
and local infusion therapy for ABO-I LDLT.
Materials and methods
Patients
Between January 2012 and February 2013, data on consecutive
patients submitted to ABO-I LDLT at the National Cancer Centre,
Goyang-si, South Korea were collected in a liver transplant data-
base. All patients were transplanted with a right lobe from a live
donor and did not undergo simultaneous splenectomy and local
infusion therapy. The same ABO-I LDLT protocol was used in all
patients. The medical records of all patients were retrospectively
reviewed for data on patient demographics, surgical procedures,
postoperative complications and follow-up information. In addi-
tion, perioperative laboratory changes in total bilirubin, pro-
thrombin time (PT), aspartate transaminase (AST) and alanine
transaminase (ALT) were analysed. The study protocol was
approved by the Institutional Review Board at the National
Cancer Centre.
Protocol for ABO-I LDLT
The current immunosuppressive regimen in ABO-compatible
LDLT involves the administration of high-dose steroids during the
operation, followed by tacrolimus and mycophenolate mofetil and
a combination of corticosteroids after transplantation. In addi-
tion, basiliximab is administered as induction therapy (20 mg on
the day of surgery and on postoperative day 4). Tacrolimus was
started within 2 days after LDLT. The target tacrolimus level in the
first month postoperatively was 10–12 ng/ml, which was titrated
down to 8–10 ng/ml over the next few months. After 1 year, a
tacrolimus trough of approximately 5 ng/ml was maintained.
Mycophenolate mofetil was started 2 days after LDLT at a dose of
1.5 g/day and titrated according to white blood cell count and
tapered off 12 months after LDLT. Steroids were tapered to dis-
continuation by 6 months after LDLT.
For ABO-I LDLT, the following three steps were added to the
basic protocol for ABO-compatible LDLT (Fig. 1). First, a single
dose of rituximab (300 mg/m2) was given 2 weeks prior to LDLT.
Second, several sessions of plasma exchange to decrease the pre-
formed anti-donor blood type isoagglutinin antibody titre to
≤1 : 8 were started at 1 week prior to LDLT. Third, a high dose of
i.v. IG (0.8 g/kg) was administered on postoperative days 1 and 4.
The immunosuppressant regimen was identical to that in ABO-
compatible LDLT.
The prophylactic regimen for ABO-I LDLT consisted of broad-
spectrum antibiotics (ticarcillin sodium/clavulanate potassium)
for 7 days, an antifungal agent (fluconazole) for 1 month, and
trimethoprim-sulfamethoxazole for 1 year. This prophylactic
regimen has a longer duration of use than that used in ABO-
compatible LDLT. Cytomegalovirus (CMV) prophylaxis was not
routinely given. Instead, CMV antigenaemia was checked twice
per week until discharge, once per week until 1 month postopera-
tively, and then every other week or once per month as pre-
emptive therapy. To prevent a rapid increase in hepatitis B and C
viral load as a result of desensitization, antiviral agents were
administered before rituximab. The prophylaxis for hepatitis B
virus (HBV) recurrence after LDLT consisted of entecavir and
hepatitis B IG. For recurrent hepatitis C virus (HCV), pegylated-
interferon and ribavirin were administered after confirmation by
biopsy or if an abnormal liver function test showed elevated HCV
RNA loads.
The routine protocol biopsy for the detection of rejection was
not performed. Instead, if liver function tests showed serum levels
of AST, ALT and total bilirubin after LDLT to be elevated two-
or three-fold higher than the normal limit without abnormal
imaging tests, a biopsy was performed. In particular instances
in which the isoagglutinin antibody titre was simultaneously
increased to over four times that on the day of surgery or over
1 : 32, and accompanied by an increased liver function test,
antibody-mediated rejection was suspected and biopsy was per-
formed. When histopathology showed portal tract oedema,
ductular reaction, and a neutrophil-rich portal inflammatory cell
infiltrate without significant acute cellular rejection, antibody-
mediated rejection was suspected. In such instances, C4d immu-
Figure 1 National Cancer Centre protocol with rituximab, plasma
exchange, basiliximab and i.v. immunoglobulin (i.v. IG) without graft
local infusion and splenectomy in ABO-incompatible living donor
liver transplantation (LDLT)
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nofluorescence staining was performed and specific linear
deposition was assumed to suggest antibody-mediated rejection.
In biopsy-proven antibody-mediated rejection, the treatment plan
included high doses of i.v. IG (1 g/kg/day), steroid pulse therapy
and plasma exchange.
Anti-blood type isoagglutinin titres and peripheral
blood CD19+ cells
The preformed anti-blood type isoagglutinin antibody titre was
tested with the immediate spin technique.15 The isoagglutinin titre
was checked before the administration of rituximab and serially
measured after the initiation of plasma exchanges. After LDLT,
isoagglutinin titre was checked daily before discharge, weekly until
1 month postoperatively, and every other week or monthly there-
after. The prevalence of peripheral blood CD19+ cells was checked
before the administration of rituximab by flow cytometry, and
immediately before LDLT to identify the effect of rituximab. After
LDLT, the lymphocyte subset panel including CD19+ B cells was
followed up twice per week until discharge, weekly until 1 month
postoperatively, and monthly thereafter.
Perioperative transfusion
In major incompatibility, transfusions of recipient blood type or
type O packed red blood cells (PRBC) and donor blood type or
type AB fresh frozen plasma (FFP) and platelets were adminis-
tered. In mixed major and minor incompatibility, transfusion of
blood type O PRBC and blood type AB FFP and platelets were
administered (Table S1, online).
Statistical analysis
Non-normally distributed quantitative variables were expressed as
the median (centile 25; centile 75). Statistical analysis was per-
formed using sas Version 9.1.3 (SAS Institute, Inc., Cary, NC,
USA).
Results
Donor and recipient characteristics
Fifteen patients (11 men, four women) underwent elective ABO-I
LDLT at the study centre according to the centre’s protocol.
Patient characteristics are summarized in Table 1. The aetiology of
liver disease included HBV infection with cirrhosis (n = 2), hepa-
tocellular carcinoma (HCC) with HBV infection (n = 11), HCV
cirrhosis (n = 1), and HCC with alcoholic cirrhosis (n = 1). Of the
12 patients with HCC, pathological findings showed seven
(58.3%) to be within the Milan criteria. The mean ± standard
deviation (SD) recipient age and Model for End-stage Liver
Disease (MELD) score were 51.8 ± 9.4 years and 11.3 ± 3.8, respec-
tively. Living donors consisted of the respective patient’s wife (n =
5), son (n = 4), brother-in-law (n = 2), husband (n = 1), sister-in-
law (n = 1), sister (n = 1) and nephew (n = 1). The mean ± SD
donor age was 40.3 ± 15.0 years. The mean ± SD graft-to-recipient
weight ratio (GRWR) was 0.83 ± 0.16. The mean ± SD operative
time was 452.7 ± 67.0 min, mean ± SD PRBC transfusion was 4.1
± 6.1 packs, mean ± SD total ischaemic time was 133.4 ± 37.8 min,
and mean ± SD postoperative hospital stay was 13.1 ± 3.0 days.
Follow-up after LDLT ranged from 3 months to 16 months.
Isoagglutinin titre and CD19+ lymphocytes
In all patients, several sessions of plasma exchange effectively
lowered the isoagglutinin titre to ≤1 : 8 before LDLT. Two patients
(Patients 1 and 5) displayed an elevated isoagglutinin titre of
≥1 : 32 at 5 days postoperatively without changes in laboratory
liver function tests. These patients were treated with one cycle of
plasma exchange to prevent further elevation. Titres were lowered
to ≤1 : 32 and maintained thereafter. Patient 12 showed a four-
fold increase in isoagglutinin titre and elevated liver function test
findings at postoperative day 5 compared with that on the day of
surgery. This patient was submitted to biopsy, two sessions of
plasma exchange, and steroid pulse therapy to differentiate acute
rejection. The titre and laboratory changes were controlled with
the therapy, and the biopsy did not reveal acute rejection.
CD19+ lymphocytes were effectively suppressed to ≤1% of all
lymphocytes with the administration of rituximab (300 mg/m2)
2 weeks before LDLT. The suppression of CD19+ lymphocytes
was continued for ≥6 months in these patients.
Patient outcomes and postoperative
laboratory changes
There were no hyperacute and antibody-mediated rejections, and
no hepatic artery and portal vein thrombosis. Three patients
(Patients 2, 3 and 5) were treated with percutaneous biliary drain-
age or endoscopic retrograde biliary drainage as a result of extra-
hepatic biliary stricture. Among 13 patients with HBV infection,
10 patients showed an undetectable viral load by polymerase
chain reaction (PCR) test under medication with entecavir or
tenofovir. However, three patients (Patients 5, 10 and 11) showed
loads of 412 234 IU/ml, 2 986 521 IU/ml and 286 274 IU/ml,
respectively, before they were submitted to a desensitization
protocol. These patients were started on antiviral agents before the
administration of rituximab. There was no HBV recurrence after
transplantation. Patient 6 showed HCV recurrence 1 month after
LDLT with an elevated liver function test. The patient was suc-
cessfully treated with a combination of pegylated interferon and
ribavirin. There was one case of positive CMV antigenaemia
(defined as antigen detection of ≥5 in 200 000 white blood cells;
Patient 10) and one disseminated herpes zoster infection (Patient
13) after LDLT. However, no patient experienced bacterial or
fungal infection after LDLT.
In this population, 12 patients underwent LDLT for HCC. After
transplantation, two patients (Patients 3 and 5) experienced
recurrent HCC with intra- and extrahepatic metastases (Patient 3
fulfilled and Patient 5 exceeded the Milan criteria). These patients
were treated with multidisciplinary approaches. However,
Patient 5 died of multiple tumour recurrence at 6 months after
transplantation.
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Laboratory changes including total bilirubin, PT, AST and ALT
after LDLT were normalized within 1 month postoperatively
without graft dysfunction.
Discussion
The demand for ABO-I LDLT is increasing among patients who
require immediate treatment when ABO-compatible donors are
unavailable. As the safety of ABO-I LDLT has been verified in
several current reports, this technique has been explored in con-
texts in which donor pools have been limited. However, additional
procedures and acute antibody-mediated rejection have made
transplant surgeons hesitant about the use of ABO-I LDLT. Of
particular concern is the fact that invasive procedures, such as
local infusion therapy through the hepatic artery or portal vein,
and splenectomy, can induce fatal complications including vascu-
lar thrombosis, massive bleeding and severe infections. Nonethe-
less, dramatic improvements in patient survival since the early
period of ABO-I LDLT have been noted.6 In the present series, the
medical process in routine LDLT was modified by including the
administration of monoclonal antibodies to B and T lymphocytes,
plasmapheresis and i.v. IG to overcome antibody-mediated rejec-
tion in ABO-I LDLT, which allowed the procedure to be per-
formed successfully in 15 consecutive patients without local
infusion therapy or splenectomy.
Local infusion therapy was reported in 1998, and involved
methylprednisolone, prostaglandin E1, and gabexate mesilate
administered via catheter through the portal vein.7 The theoretical
basis of these local infusion agents is that they inhibit different key
reactions in single-organ disseminated intravascular coagulation
triggered by preformed antibodies against the donor antigen.16
Meanwhile, hepatic artery infusion therapy was introduced to
avoid portal vein thrombosis by portal vein infusion therapy.17
These local infusion methods have resulted in an increase in graft
survival after ABO-I LDLT from approximately 40% to 60% since
2002.8 However, catheter-related complications, including vascular
thrombosis, infection, bleeding and dislocation, have been
reported to occur in 37% of patients submitted to portal vein
infusion therapy, 22% of patients submitted to portal vein and
hepatic artery infusion therapy, and 16% of patients submitted to
hepatic artery infusion therapy.6 These complications can be life-
threatening. Recently, Kim et al. showed no difference in liver
function tests between patients undergoing local infusion therapy
and systemic infusion, respectively.18 In addition, splenectomy has
been an important part of ABO-I LDLT in many centres because
the spleen is considered a site of B cell maturation and antibody
production.6,9,11,19 The clinical significance of splenectomy in
ABO-I organ transplantation in the post-rituximab era is contro-
versial.14 In addition to antibody production, the spleen assumes
haemato-immunological functions in the filtration and storage of
blood, phagocytosis and destruction of erythrocytes, antigen
uptake, and potential haematopoiesis. Splenectomy can create risks
for postoperative portal vein thrombosis and post-splenectomy
infection.12,13 Splenectomy is time-consuming and can cause
massive bleeding as a result of splenomegaly in patients with severe
liver cirrhosis. Therefore, a recent trend towards the omission of
splenectomy in ABO-I LDLT has emerged with the prophylactic
use of rituximab.
Rituximab is a monoclonal chimeric human-murine anti-
CD20 antibody that depletes B cells by complement-dependent
cytotoxicity and antibody-dependent cell-mediated cytotoxicity.
CD20 antigen is expressed on most B cells except stem cells, pro-
B cells and plasma cells. Previously, this group used CD19 as a
surrogate marker in patients with circulating rituximab because
CD19 is expressed from pro-B cells to memory B cells except stem
cells and plasma cells, and mirrors CD20 expression.20 Following
the introduction of prophylaxis in ABO-I LDLT in 2002, the sys-
tematic use of rituximab from the preoperative period has been
emphasized to avoid antibody-mediated rejection. The current
strategy for ABO-I LDLT at this institution is to administer a
single dose of rituximab 300 mg/m2 at 2 weeks prior to surgery.
Since the early period of ABO-I LDLT, a large dose or multiple
administrations of rituximab, such as in the treatment of B cell
leukaemia, have come to be considered unnecessary in view of the
risk for postoperative infection. Instead, a single administration of
a small dose has been accepted since the kinetics of B cells in
ABO-I LDLT became better understood.5,14 Furthermore, 2–3
weeks has been reported as sufficient to perceive the effect of
rituximab.21 In the present study, B cell levels in all patients were
lowered to ≤1% at surgery 2 weeks after the administration of
rituximab. The effect of rituximab was sustained for at least 6
months after administration. Plasma exchange was performed to
reduce circulating anti-ABO antibodies, and was started within 1
week prior to LDLT using blood type AB FFP and albumin. The
target isoagglutinin level was ≤1 : 8. An isoagglutinin target of
1 : 32 is relatively safe. However, a strict target was set because
the preoperative procedure did not include the provision of
mycophenolate mofetil and splenectomy. When the titre was
increased four times compared with the level on the day of
surgery, a prophylactic plasma exchange was performed to prevent
further elevation and antibody-mediated rejection (in Patients 1,
5 and 12). The titres of these patients were decreased after one or
two sessions of plasma exchange without acute rejection. The
catheter for plasma exchange was removed at postoperative day 7
in patients without immunological failure. No serious catheter-
related infections occurred in this study.
Basiliximab is a chimeric mouse-human monoclonal antibody
to CD25 of the interleukin (IL)-2 receptor located on the surface
of activated T lymphocytes. It inhibits T lymphocyte proliferation
driven by IL-2 and prevents acute rejection in liver transplants.
This monoclonal antibody acts by saturating the receptors and
preventing T cells from replicating, and by preventing B cell acti-
vation that is necessary for the production of antibodies. In the
present study, two doses of basiliximab 20 mg were administered
on, respectively, the day of surgery and postoperative day 4. T cell
kinetics after rituximab treatment are unclear. However, in the
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present series, the proportion of helper T cells was increased for
almost 1 month after ABO LDLT (data not shown). Basiliximab
had been expected to restrict helper T cell activation and restrict
the manufacture of antibodies because the B cells in the lymph
node and spleen were not eliminated by rituximab. Furthermore,
i.v. IG (0.8 g/kg) was administered on postoperative days 1 and 4.
The mechanisms of action of i.v. IG have been suggested to
include the blockade of Fc receptors on mononuclear phagocytes,
the direct neutralization of alloantibodies, the inhibition of
expression of CD19 on activated B cells, the inhibition of comple-
ment and the inhibition of alloreactive T cells. The successful use
of i.v. IG without local graft infusion has been reported previ-
ously.5 However, these authors employed routine splenectomy in
their ABO-I LDLT protocol.5 In ABO-I organ transplantation, i.v.
IG is used in emergency transplant settings, such as in acute liver
failure, in which the early administration of rituximab is not
possible, and for rescue therapy for antibody-mediated rejec-
tion.4,5 In the present series, prophylactic i.v. IG administration
synergistically improved outcomes in relation to the suppression
of humoral reaction with rituximab, although splenectomy, local
graft infusion and preoperative mycophenolate mofetil were not
used. Moreover, i.v. IG has been used for the treatment of sepsis
because neutralizing and opsonizing antibodies can inactivate
bacterial endotoxins and exotoxins, stimulate leukocytes, and
increase serum bactericidal activity. In the ABO-I LDLT setting,
high-dose rituximab, plasmapheresis, splenectomy and aggressive
immunosuppression markedly increase the risks for postoperative
bacterial, fungal and viral infection.6 In the present study, no
bacterial or fungal infections were evident after LDLT. Only one
positive CMV antigenaemia and one herpes zoster infection
were detected among 15 patients without prophylactic antiviral
therapy, and both were treated successfully. Intravenous IG might
be helpful to prevent antibody-mediated rejection and postopera-
tive infection in ABO-I LDLT without splenectomy and local graft
infusion.
The recurrence of hepatitis virus after ABO-I LDLT was con-
cerning in view of the aggressive immunosuppression of B lym-
phocytes. There was no recurrence of HBV in this study using the
prophylactic therapy with a combination of hepatitis B IG and
entecavir. However, the one patient enrolled with HCV infection
did experience recurrence of HCV early after LDLT. In another
recent study, all patients who underwent ABO-I LDLT for HCV
infection experienced recurrence.22 In addition, patients in whom
the hepatitis C viral load increased steeply early after LDLT experi-
enced fluctuating liver function test results with a rapid increase in
total bilirubin after LDLT. In the present study, the patient infected
with HCV displayed a 20-fold increase in the viral RNA load at 1
month post-transplantation, with increased liver function find-
ings, compared with the pre-transplant viral load. Therapy using
pegylated interferon and ribavirin controlled the viral load. In the
event of HCV recurrence, a prophylactic or pre-emptive treatment
protocol might be needed in ABO-I LDLT. It is notable that the
present series included a large proportion of patients with HCC
(n = 12, 80.0%). Among these, two patients (Patients 3 and 5)
experienced tumour recurrence at <6 months after LDLT,
although the tumour in Patient 3 fell within the Milan criteria.
The correlations supporting tumour recurrence in ABO-I LDLT
are not well known; it is conceivable that severe immunosuppres-
sion may weaken the natural anti-tumour immune system and
that tumour may be more likely to recur than in ABO-compatible
LDLT. As cases accumulate, it is anticipated that the criteria for
selecting ABO-I LDLT for HCC patients will become distinct from
those for ABO-compatible LDLT.
Finally, the practical challenges in the application of ABO-I
LDLT refer to its high cost. In the present study protocol, medi-
cations including a single dose of rituximab, several sessions of
plasma exchange, two doses of basiliximab, and two doses of i.v.
IG were used. Although the cost of these medications depends on
the country and insurance system in place, the high costs of ABO-I
LDLT place a heavy burden on both patients and clinicians.
However, as the mechanism of antibody-mediated rejection
becomes elucidated, it may become possible to minimize the
desensitization protocol and reduce costs.
In conclusion, this simplified ABO-I LDLT protocol using
rituximab, plasma exchange, basiliximab and i.v. IG without graft
local infusion and splenectomy showed good graft outcomes
without hyperacute or antibody-mediated rejection. This protocol
describes a simple and effective mode of treatment for ABO-I
LDLT.
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Table S1. Blood product selection in perioperative ABO-incompatible liver
transplantation.
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